Alleyasin Tara, Wilder Evan, Reidel Warren, Du Emma, Nhu Quan M
Department of Internal Medicine, Scripps Clinic/Green Hospital, San Diego, CA.
Division of Gastroenterology and Hepatology, Scripps Clinic/Green Hospital, San Diego, CA.
ACG Case Rep J. 2025 May 30;12(6):e01716. doi: 10.14309/crj.0000000000001716. eCollection 2025 Jun.
Autoimmune enteropathy (AIE) is a rare condition characterized by immune-mediated villous atrophy with associated chronic diarrhea. In this case, a 34-year-old man with AIE was treated with vedolizumab, an anti-ɑ4b7 integrin that inhibits intestinal lymphocyte trafficking, after initial treatments with prednisone, open-capsule budesonide, azathioprine, infliximab, and adalimumab showed minimal response. Vedolizumab resulted in moderate symptomatic and histological improvement but was discontinued due to possible drug-induced liver injury. This case suggests the potential therapeutic efficacy of vedolizumab in treating AIE, though more research is needed.
自身免疫性肠病(AIE)是一种罕见疾病,其特征为免疫介导的绒毛萎缩并伴有慢性腹泻。在此病例中,一名患有AIE的34岁男性患者,在最初使用泼尼松、开放胶囊型布地奈德、硫唑嘌呤、英夫利昔单抗和阿达木单抗治疗后反应甚微,随后接受了维得利珠单抗治疗,这是一种抑制肠道淋巴细胞迁移的抗ɑ4b7整合素。维得利珠单抗使症状和组织学得到了中度改善,但因可能的药物性肝损伤而停药。该病例提示维得利珠单抗在治疗AIE方面可能具有治疗效果,不过仍需更多研究。